SATURDAY, JUNE 24, 2017

Agenus testing shows promising results for herpes vaccine

Agenus Inc. -- an immune-oncology company that creates heat shock protein peptide-based vaccines, checkpoint modulators (CPMs), and adjuvants -- recently announced promising results from its HerpV synthetic vaccine Phase 2 trial. Read More »

First measles case of 2015 confirmed in Massachusetts

A recent announcement from the Hinton State Laboratory has confirmed the first measles case for 2015 in the state of Massachusetts. Read More »

Merck re-commits to innovative infectious disease medicines

At the 25th European Congress of Clinical Microbiology and Infectious Diseases in Copenhagen, Denmark, Merck will re-commit itself to creating innovative medicines to treat infectious diseases as health professionals around the world battle infectious illnesses from various pathogens. Read More »

Study shows anti-virals battle HIV via mutational meltdown

Researchers from the Massachusetts Institute of Technology (MIT) and the University of Chicago recently created a spectroscopy method that illustrates how anti-HIV drugs provoke lethal mutations within HIV’s genetic material, a discovery that sheds light on a process that has been poorly understood in the past and may improve attempts to create novel anti-viral treatments. Read More »

Spring Bank Pharmaceuticals to present HBV and HCV treatment candidate

Spring Bank Pharmaceuticals Inc., a clinical-stage biopharmaceutical company that creates novel therapeutics to treat viral infections, has recently announced that a company representative will present its lead drug candidate, SB 9200, for treating infections of hepatitis B virus (HBV) and hepatitis C virus (HCV). Read More »

VBI Vaccines and Sanofi Pasteur partner to increase vaccine stability

According to a recent announcement from VBI Vaccines Inc., VBI has partnered with Sanofi Pasteur to improve the stability of vaccines. Read More »

Alere supports Obama’s National Action Plan to combat Antibiotic-Resistant Bacteria

Alere Inc., a rapid diagnostics company, has formally announced its support of President Barack Obama's National Action Plan to combat Antibiotic-Resistant Bacteria. Read More »

Data suggest low vaccination rates, measles outbreak related

Researchers at Boston Children’s Hospital recently published a report from epidemiological data that suggest there is a correlation between low vaccination rates and the measles outbreak of 2015. The researchers said the general population has received far fewer vaccines than what is needed to stop a measles outbreak. Read More »

New UK study unveils stronger vaccine to fight HPV

Scientists have developed a new HPV vaccine that potentially protects against nine types of the virus. Read More »

Vaxxas set to develop Nanopatch 'needle-free' vaccines

Vaxxas said this week that it has raised $20 million for a series of clinical programs toward development of a line of vaccine products using the company's Nanopatch platform, which utilizes painless microneedles. Read More »

Vaxxas secures $20 million for Nanopatch vaccine programs

Biotechnology company Vaxxas said on Monday that it has obtained $20 million in equity funding from new and existing investors. Read More »